Jian Yang

Jian Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jian Yang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • De-Jun Liu

    Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Hongfei Yao

    Department of General Surgery, Pancreatobiliary Surgery Center, Huadong Hospital, Fudan University, Shanghai 200040, China

    1 shared publication
  • Jia-Hao Zheng

    Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

    1 shared publication
  • Jian-Yu Yang

    Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, P.R. China

    1 shared publication
  • Li Chen

    Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Pei Xuan Ji

    Department of Gastroenterology, Renji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases Shanghai China

    1 shared publication

Latest Publications

  • Open Access

    Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma

    by Jia-Hao Zheng, Hong-Fei Yao, Zong-Hao Duan, Pei-Xuan Ji, Jian Yang, Yu-Heng Zhu, Qin-Yuan Jia, Jian-Yu Yang, De-Jun Liu, Yong-Wei Sun, et al.

    Pancreatic adenocarcinoma (PAAD), one of the most malignant tumors, not only has abundant mesenchymal components, but is also characterized by an extremely high metastatic risk. The purpose of this study was to construct a model of stroma- and metastasis-associated prognostic signature, aiming to benefit the existing clinical staging system and predict the prognosis of patients. First, stroma-associated genes were screened from the TCGA database with the ESTIMATE algorithm. Subsequently, transcriptomic data from clinical tissues in the RenJi cohort were screened for metastasis-associated genes. Integrating the two sets of genes, we constructed a risk prognostic signature by Cox and LASSO regression analysis. We then obtained a risk score by a quantitative formula and divided all samples into high- and low-risk groups based on the scores. The results demonstrated that patients with high-risk scores have a worse prognosis than those with low-risk scores, both in the TCGA database and in the RenJi cohort. In addition, tumor mutation burden, chemotherapeutic drug sensitivity and immune infiltration analysis also exhibited significant differences between the two groups. In exploring the potential mechanisms of how stromal components affect tumor metastasis, we simulated different matrix stiffness in vitro to explore its effect on EMT key genes in PAAD cells. We found that cancer cells stimulated by high matrix stiffness may trigger EMT and promote PAAD metastasis.